GSK (LON:GSK) Insider Purchases £130.74 in Stock

GSK plc (LON:GSK) insider Julie Brown acquired 6 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was bought at an average price of GBX 2,179 per share, with a total value of £130.74.

GSK Trading Up 1.1%

LON:GSK opened at GBX 2,165 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK plc has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 2,219. The firm has a market capitalization of £87.35 billion, a price-to-earnings ratio of 16.28, a PEG ratio of 1.24 and a beta of 0.31. The business’s 50-day moving average price is GBX 1,880.92 and its two-hundred day moving average price is GBX 1,693.82.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Shore Capital Group reiterated a “buy” rating and issued a GBX 2,300 target price on shares of GSK in a report on Wednesday, February 4th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,100 price objective on shares of GSK in a research report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft lifted their target price on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a report on Thursday, January 15th. UBS Group reissued a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a research note on Friday, January 23rd. Finally, Citigroup raised their price target on GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research report on Monday, February 9th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.